Compare Abeona Therapeutics Inc (ABEO) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Newegg Commerce Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Newegg Commerce Inc trades at $19.76 (market cap $398.29M). The key difference: Abeona Therapeutics Inc and Newegg Commerce Inc are close in size by market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | NEGG | |
|---|---|---|
Market Cap | $421.19M | $398.29M |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $128.09 |
52-Week Low | $4.17 | $12.87 |
Enterprise Value | $276.10M | $397.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Newegg Commerce (NEGG) trades at $19.80, up 7.73% with bullish technical signals and strong recent earnings beats. The stock shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 forecasts. Recent business developments include AI shopping enhancements and exclusive product launches driving growth potential.
Outlook remains cautiously optimistic with improving profitability but carries execution risks. The high P/E ratio of 73.16 suggests premium valuation requiring sustained growth. Key opportunities include technology sector recovery and AI initiatives, while risks involve competitive pressures and cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
